Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

Why biotech companies are often at the whim of things they cannot control, in one chart

  • Damian Garde

By Damian Garde July 31, 2019

Reprints
UnoQure chart
Damian Garde/STAT

A version of this story first appeared in STAT’s free biotech newsletter, The Readout. Sign up here to subscribe.

Sometimes, the market delivers tidy reminders that biotech companies are often at the whim of things they cannot control.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Tags

A half century after Prozac, a new generation of…
A half century after Prozac, a new generation of depression drugs is bringing hope to a…
Wary of changes to Medicare Advantage, health insurers put…
Wary of changes to Medicare Advantage, health insurers put up a fight — and exaggerate the…
Human reproductive cloning: The curious incident of the dog…
Human reproductive cloning: The curious incident of the dog in the night-time
With new study data, Intra-Cellular could expand use of…
With new study data, Intra-Cellular could expand use of approved mood-disorder treatment
Viking Therapeutics releases early but promising weight loss data…
Viking Therapeutics releases early but promising weight loss data on new GLP-1 drug
Novartis data set up multibillion-dollar battle over breast cancer…
Novartis data set up multibillion-dollar battle over breast cancer drugs

Recommended Stories